Arbutus Opens $230 Million Dutch Auction Tender at $5.00 to $5.75 a Share, Enough to Retire Up to 23.2% of Its Stock

by Ellis Vance · August 24, 2026

Small-Cap Markets Correspondent, The SmallCap Signal

Arbutus Biopharma Corporation (Nasdaq: ABUS) commenced a modified "Dutch auction" tender offer on Aug. 24 to buy back up to US$230 million in value of its own common shares. According to the company's Aug. 24 release, holders may tender at prices of not less than US$5.00 and not more than US$5.75 per share, in increments of US$0.05, and a fully subscribed offer would represent between 20.2% and 23.2% of the shares currently issued and outstanding.

The release puts the share count at 198,105,743 as of Aug. 19, 2026. Those percentages reconcile with the offer's own terms: at the top of the range, US$230 million buys 40,000,000 shares, or 20.2% of that count; at the bottom, it buys 46,000,000 shares, or 23.2%. The offer will expire at 5:00 p.m. New York City time on Sept. 29, 2026, unless Arbutus extends or terminates it. In a modified Dutch auction, the company sets a range and shareholders choose the price at which they are willing to sell; the release states that all shares purchased in the offer will be acquired at the same purchase price regardless of whether any shareholder tendered at a lower price.

Two features of the structure matter to smaller holders. The Aug. 24 release describes an odd-lot provision under which the company will purchase all shares validly tendered at or below the purchase price by shareholders who own fewer than 100 shares and who tender all of the shares they own. The release also states that neither Arbutus' management nor any member of its board of directors or its executive officers makes any recommendation to shareholders as to whether to tender or refrain from tendering, leaving shareholders to decide how many shares to tender, if any, and at what price within the range.

The cash is settlement money. Arbutus said the offer will be funded from cash on hand, including approximately US$178 million received on July 8, 2026 as its share of the noncontingent payment under the settlement agreement entered into with Moderna, Inc. resolving patent litigation over lipid nanoparticle delivery technology. That is a larger sum than the company's own balance sheet carried at mid-year: the Aug. 12 second-quarter release reported US$92.6 million in cash, cash equivalents and marketable securities as of June 30, 2026.

The underlying settlement was announced on March 3, 2026 by Arbutus and Genevant Sciences and valued at US$2.25 billion in total, according to that release, consisting of US$950 million upfront in July 2026 and US$1.3 billion contingent on an appellate ruling that 28 U.S.C. Section 1498 does not bar the infringement claims, except as to doses the district court characterized as having gone to U.S. government employees. The March release says the agreement resolves all U.S. and international enforcement actions involving Moderna's unauthorized use of the two companies' LNP delivery technology in its COVID-19 vaccines, that Genevant agreed to grant Moderna a global non-exclusive license to LNP delivery technology for infectious disease applications along with a covenant not to sue, and that Moderna consented to entry of a judgment of infringement and of no invalidity of four Genevant/Arbutus patents. The release did not disclose how the total is split between Genevant and Arbutus.

The Aug. 24 release also sets out who is expected to participate. It identifies Roivant Sciences Ltd. as the beneficial owner of 38,847,462 shares, or approximately 19.6%, and says Roivant intends to make a proportionate tender — a feature for which Arbutus said it obtained exemptive relief from the U.S. Securities and Exchange Commission. Directors and officers have indicated an intent to tender an aggregate of up to 682,630 shares through purchase price tenders. The company said that on Aug. 21, 2026 it obtained exemptive relief from the applicable Canadian securities regulatory authorities. J.P. Morgan Securities LLC is acting as dealer manager. The Aug. 21 announcement of intent flagged a commencement of the offer on or about Aug. 24 and an expiration on or about Sept. 29.

The buyback lands on a business that is small and getting smaller in operating terms. Arbutus reported total revenue of US$1.0 million for the second quarter of 2026, down from US$10.7 million a year earlier, and a GAAP net loss of US$5.1 million, or US$0.03 per basic and diluted share on a weighted average 197.5 million shares, according to the Aug. 12 results release. Research and development expense was US$2.9 million, down US$2.6 million from a year earlier, and general and administrative expense was US$3.9 million. The company attributed the R&D decline primarily to cost savings from its decisions to reduce its workforce and discontinue in-house scientific research, as well as lower clinical trial costs as studies neared completion.

What remains is a narrow clinical program. The Aug. 24 release identifies imdusiran (AB-729) and an oral PD-L1 inhibitor, AB-101, for the treatment of chronic hepatitis B infection, along with the intellectual property licensing relationship with Genevant covering LNP technology. In the Aug. 12 release, president and chief executive Lindsay Androski said, "This has been an exciting quarter for our imdusiran development program," citing Fast Track designation granted by the U.S. Food and Drug Administration in April 2026 and alignment reached with the agency in May 2026 on the design of a Phase 2b clinical trial. The company said it plans to incorporate that feedback into a final Phase 2b protocol; the Aug. 12 release gave no start date for the study.

The documents also set out what the offer does not commit to. The Aug. 24 release states that the offer is not conditioned upon the receipt of any financing or upon any minimum number of shares being tendered, but is subject to a number of other terms and conditions described in the offer to purchase and bid circular. It warns that an election to accept the purchase price determined in the offer may result in a price below the recent closing price and could be below the reported closing price on the expiration date, and it describes proration if auction tenders exceed the amount the company is seeking. Because there is no minimum, the amount of capital ultimately returned — and therefore the cash left to fund a Phase 2b hepatitis B program at a company with roughly US$1 million of quarterly revenue — will not be known until after the Sept. 29 expiration and the proration process that follows. The board's decision not to make a recommendation leaves that trade-off explicitly with shareholders.